Search result for 'alopecia areata'

Sun Pharma's LEQSELVI (deuruxolitinib) receives USFDA approval for treating severe alopecia areata in adults. This new drug offers hope for patients with this autoimmune disorder causing hair loss.

Sun Pharma has secured exclusive rights to deuruxolitinib for treating alopecia areata and androgenetic alopecia from Aclaris Therapeutics. The agreement includes an upfront payment of USD 15 million.

Sun Pharma shares rallied over 2.5% on Wednesday after the company reported a 5% increase in consolidated net profit for the September quarter, driven by strong sales in India and the US.

Sun Pharma's consolidated net profit rose 5% to Rs 2,375 crore in Q2 FY24, driven by strong sales in India and the US. The company also highlighted key milestones in its drug development pipeline.